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Abstract
Background: We analyzed the influence of 8 germinal polymorphisms of candidate genes potentially related to
EGFR signalling (EGFR, EGF, CCND1) or antibody-directed cell cytotoxicity (FCGR2A and FCGR3A) on outcome of
colorectal cancer (CRC) patients receiving cetuximab-based therapy.
Methods: Fifty-eight advanced CRC patients treated with cetuximab-irinotecan salvage therapy between 2001 and
2007 were analyzed (mean age 60; 50 PS 0-1). The following polymorphisms were analyzed on blood DNA: EGFR
(CA repeats in intron 1, -216 G > T, -191C > A, R497K), EGF (A61G), CCND1 (A870G), FCGR2A (R131H), FCGR3A
(F158V). Statistical analyses were conducted on the total population and on patients with wt KRas tumors. All SNPs
were considered as ternary variables (wt/wt vs wt/mut vs mut/mut), with the exception of -191C > A EGFR
polymorphism (AA patient merged with CA patients).
Results: Analysis of skin toxicity as a function of EGFR intron 1 polymorphism showed a tendency for higher
toxicity in patients with a low number of CA-repeats (p = 0.058). CCND1 A870G polymorphism was significantly
related to clinical response, both in the entire population and in KRas wt patients, with the G allele being
associated with a lack of response. In wt KRas patients, time to progression (TTP) was significantly related to EGFR
-191C > A polymorphism with a longer TTP in CC patients as compared to others, and to CCND1 A870G
polymorphism with the G allele being associated with a shorter TTP; a multivariate analysis including these two
polymorphisms only retained CCND1 polymorphism. Overall survival was significantly related to CCND1
polymorphism with a shorter survival in patients bearing the G allele, and to FCGR3A F158V polymorphism with a
shorter survival in VV patients (in the entire population and in KRas wt patients). FCGR3A F158V and CCND1 A870G
polymorphisms were significant independent predictors of overall survival.
Conclusions: Present original data obtained in wt KRas patients corresponding to the current cetuximab-treated
population clearly suggest that CCND1 A870G polymorphism may be used as an additional marker for predicting
cetuximab efficacy, TTP and overall survival. In addition, FCGR3A F158V polymorphism was a significant
independent predictor of overall survival.
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Despite the introduction of new treatments, the 5-year
survival rate for metastatic colorectal cancer (mCRC)
remains below 10% [1]. Cetuximab, an IgG1 monoclonal
antibody (MoAb) targeting epidermal growth factor
receptor (EGFR), has proven to be effective in providing
clinical benefit in approximately 10% to 20% of patients
[2-4]. EGFR is a transmembrane tyrosine kinase receptor
that, following ligand binding, triggers two main signal-
ing pathways: the RAS-RAF-MAPK pathway which is
involved in cell proliferation, and the PI3K-PTEN-AKT
pathway which controls cell survival and motility [5].
While the presence of a KRAS mutation permits iden-
tification of tumors that are insensitive to these treat-
ments, only less than half of patients with a KRAS wild
type (wt) tumor will benefit from treatments, suggesting
a role for additional mechanisms of resistance [6-10]. It
thus appears necessary to better define the subpopula-
tion of patients who truly benefit from cetuximab. One
approach to resolving this question may be the applica-
tion of pharmacogenetics, as recently reviewed by Coate
and co-workers [11]. Yet, gene polymorphisms may
affect pharmacodynamics of anti-EGFR therapies such
as cetuximab, by introducing inter-patient variability at
the level of the EGFR target itself, the EGF ligand, as
well as in the immunological mechanism called anti-
body-dependent cellular cytotoxicity (ADCC).
Four functional EGFR variants have been associated
with EGFR regulation [12-14]: a (CA)n repeat poly-
morphism in EGFR intron 1, a G > A single nucleotide
polymorphism (SNP) at codon 497, and two SNPs -216
G > T and -191C > A located in the promoter region.
Modulation of the EGFR ligand EGF and of the down-
stream EGFR signaling, including the cyclin-D1 gene
(CCND1), may also play a role in modulating cetuximab
activity. Functional variants have been described in the
EGF 5’-untranslated region (EGF 61 G > A) [15,16], and
in the exon 4 of the CCND1 gene (870A > G) [17,18].
The ADCC, mediated through Fc receptors (FcgR) car-
ried by immune cells such as macrophages and natural
killer cells, plays an important role in the antitumor
effect of IgG1 antibodies, such as cetuximab [19,20].
The effectiveness of ADCC may depend on the degree
of activation of FcgR and constitutional polymorphisms
have been demonstrated on genes encoding for these
receptors: a histidine (H)/arginine (R) polymorphism at
position 131 for FCGR2A and a valine (V)/phenylalanine
(F) polymorphism at position 158 for FCGR3A [21].
In the present study, we investigated possible associa-
tions between these genetic variants and clinical outcomes
of advanced CRC patients treated with cetuximab. Clinical
end points were skin toxicity, clinical response, time to
progression (TTP) and overall survival (OS).
Materials and methods
Patients
Fifty-eight patients with advanced colorectal carcinoma
were included in this retrospective pharmacogenetic
study. All were treated between December 2001 and
November 2007. Forty-four patients were treated at the
H ô p i t a lL aT i m o n ea n d1 4a tt h eH ô p i t a lN o r d( M a r -
seille). The study was carried out with ethics committee
approval and patients signed a specific informed consent
for pharmacogenetic analyses. Patient characteristics are
s h o w ni nT a b l e1 .F o r m a l i n - f ixed, paraffin-embedded
tumor material was collected retrospectively for 50
patients. After histological control (HES) and macro-
dissection to select tumor areas containing at least 50%
Table 1 Patient characteristics (N = 58)
Age (years) Mean 60.2
Range 32-83
Gender Men 36
Women 22
PS 02 8
12 2
26
32
Adjuvant chemotherapy No 41
Yes 17
Primary tumor localization Right colon 6
Left colon 30
Rectum 21
Unknown 1
Metastasis characteristics Single 23
Multiple 35
Synchronous 36
Metachronous 22
KRAS mutation status Non-mutated 34
Mutated at
codon 12 or 13
16
Unknown 8
Previous administration of
bevacizumab for metastatic disease
No 45
Yes 13
Line of cetuximab treatment First 1
Second 8
Third 32
≥ 4
th 17
Chemotherapy associated with
cetuximab
None 2
Irinotecan 41
FOLFIRI 14
FOLFOX 1
Number of cetuximab cycles Mean 7.6
Median 6.0
Range 1-29
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Page 2 of 11tumor cells, DNA was extracted, and activating muta-
tions of KRAS gene at codon 12 and codon 13 were
analyzed by direct sequencing (Big Dye Terminator
cycle sequencing kit, Applied Biosystems, Foster City,
CA) on a 3130 genetic analyzer (Applied Biosystems). A
KRAS mutation was detected in 32% of patients (16/50).
T h em a j o r i t yo fp a t i e n t s( 5 5 % )r e c e i v e dc e t u x i m a ba s
third-line therapy, and the associated chemotherapy was
irinotecan for 71% of patients. Thirteen patients out of
58 had received previous therapy with bevacizumab for
their metastatic disease. Cetuximab was administered i.v.
over 2 hr at day1-day8-day15 (400 mg/m
2 starting dose,
250 mg/m
2 for subsequent doses, 21-day cycles). Treat-
ment was administered until disease progression or
unacceptable toxicity.
Toxicity evaluation
Toxicity evaluation focused on cetuximab-related toxi-
city, i.e. acneiform rash. The maximum observed toxicity
grade was recorded for all patients (N = 58), according
to NCI-CTCAE v3.0.
Efficacy evaluation
Best clinical response, assessed according to modified
RECIST criteria, was assessable on 56 patients (2
patients were not evaluated because of early treatment
interruption due to toxicity). Time to progression (TTP)
and specific survival (cancer-related death) were com-
puted from day-1 of cetuximab treatment. At time of
analysis, 51 patients out of 56 assessable patients had
progressed. Survival was recorded in 57 patients among
whom 44 had died from their cancer and one had died
from an independent cause. Median follow-up was 39.2
months (reverse Kaplan-Meier method).
Pharmacogenetic analyses
Germinal polymorphisms of EGFR, EGF, CCND1,
FCGR2A and FCGR3A genes, potentially linked to
cetuximab pharmacodynamics, were analyzed on DNA
extracted from a 9 ml blood sample (Paxgene Blood
DNA kit, Prenalytics). With the exception of the EGFR
intron-1 polymorphism, all other variants were investi-
gated using a polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) method
(Table 2). Electrophoresis separation was performed on
a 3% agarose gel. The CA-repeats polymorphism in
intron 1 of EGFR gene was analyzed by fluorescent
genotyping on CEQ-8000 Beckman-Coulter, as pre-
viously described [22]. Due to the large number of
genotypes (between 14 and 20 CA repeats), patients
were split into 2 groups (patients with the sum of CA
repeats ≤ 35 vs others). Wild-type and mutated cell
lines were used as controls.
Statistics
The Exact p values for Hardy-Weinberg equilibrium
were tested on http://innateimmunity.net/IIPGA2. All
SNPs were considered as ternary categorical variables
(wt/wt vs wt/mut vs mut/mut), with the exception of
-191C > A EGFR polymorphism for which the only AA
patient was merged with heterozygous patients. Non-
parametric tests were performed for comparisons
(Mann-Whitney or Kruskal-Wallis). Pearson chi-square
tests were applied for categorical variables, including
linkage disequilibrium analyses. A logistic model was
applied for estimation of odds ratio (OR) associated
with toxicity (1 = grade 2-3, 0 = grade 0-1) or response
( 1=C R + P R ,0=S D + P D ) .T T Pa n ds u r v i v a lc u r v e s
were plotted according to the Kaplan-Meier method.
Table 2 Characteristics of the PCR-RFLP methods used
Gene SNP Restriction
Enzyme
Primers
EGFR 497R > K
rs2227983
BstNI 5-TGCTGTGACCCACTCTGTCT-3
5-CCAGAAGGTTGCACTTGTCC-3
EGFR -216 G > T
rs712829
BseRI 5-CCACCGCCTCCGGCGGCCGCTGGCCTTG-3
5-CGGCGAGACACGCCCTTACCTTT-3
EGFR -191C > A
rs712830
SacII 5-CCACCGCCTCCGGCGGCCGCTGGCCTTG-3
5-CGGCGAGACACGCCCTTACCTTT-3
EGF 61A > G
rs4444903
AluI 5-TGTCACTAAAGGAAAGGAGGT-3
5-TTCACAGAGTTTAACAGCCC-3
CCND1 870A > G
rs603965
ScrFI 5-GTGAAGTTCATTTCCAATCCGC-3
5-GGGACATCACCCTCACTTAC-3
FCGR2A 131R > H
rs1801274
BstUI 5-GGAAAATCCCAGAAATTCTCGC-3
5-CAACAGCCTGACTACCTATTACGCGGG-3
FCGR3A 158F > V
rs396991
NlaIII First PCR:
5-ATATTTACAGAATGGCACAGG-3
5-GACTTGGTACCCAGGTTGAA-3
Second PCR:
5-ATCAGATTCGATCCTACTTCTGCAGGGGGCAT-3
5-ACGTGCTGAGCTTGAGTGATGGTGATGTTCAC-3
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and survival was assessed by means of Log Rank test, or
Cox analysis (for continuous variables or multivariate
analysis). For stepwise multivariate analyses, the prob-
abilities for entry and removal were 0.05 and 0.10,
respectively. Whatever the gene polymorphism and the
clinical end-point, we firstly performed univariate ana-
lyses, and then included the significant genotypes (p ≤
0.050 from univariate analyses) in a single multivariate
analysis. In addition, for efficacy end-points (response,
TTP and survival), we conducted additional univariate
and multivariate analyses on the sub-population of KRas
wt patients. The p value considered as statistically signif-
icant (p ≤ 0.05, two-sided test) was not corrected for
multiple testing. Statistics were performed on SPSS
software (v15.0).
Results
Description of gene polymorphisms
Table 3 depicts the frequency of analyzed genotypes.
Regarding intron 1 EGFR polymorphism, homozygous
16-16 CA repeats was the most frequent genotype
(29.3%), followed by heterozygous 16-20 CA repeats
(22.4%) and 16-18 CA repeats (10.3%). All bi-allelic gen-
otypes agreed well with those predicted by the Hardy-
Weinberg equilibrium. No linkage disequilibrium was
observed between EGFR -216 G > T, -191C > A and
R497K polymorphisms, nor between FCGR2A H131R
and FCGR3A V158F polymorphisms. Tumoral K-Ras
mutation status was not related to polymorphisms of
genes linked to the EGFR pathway (EGFR, EGF,
CCND1).
Impact of gene polymorphisms on toxicity
Maximum observed cetuximab-related acneiform rash
was grade 0 in 7 patients, grade 1 in 14 patients, grade
2 in 28 patients and grade 3 in 9 patients, accounting
for a total of 63.8% toxicity grade 2-3. This toxicity was
not related to performance status or patient age, but
was unexpectedly linked to patient gender, with a signif-
icantly greater toxicity in men as compared to women
(77.8% vs 40.9%, p = 0.005).
A tendency was observed for greater cutaneous toxi-
city in patients bearing short CA repeats in intron 1 of
EGFR gene, with 72.7% grade 2-3 in patients with CA
sum ≤ 35 vs 47.8% in patients with CA sum > 35 (Figure
1, p = 0.058, OR = 2.91, 95% CI 0.95-8.92). No relevant
relationship was observed for the other analyzed
polymorphisms.
Impact of gene polymorphisms on response
Best clinical response was CR in one patient, PR in 5
patients, stabilization in 11 patients and progression in
39 patients (i.e. 10.7% response rate, CR+PR). Even
though response rate was greater in patients developing
cutaneous toxicity (13.9% in patients with grade 2-3 vs
5.0% in patients with grade 0-1), this difference did not
reach statistical significance (p = 0.30). In other respects,
response rate was 15.2% in patients with non-mutated
KRas tumors vs 0% in patients with KRas mutated
tumors (p = 0.11).
Regarding gene polymorphisms, CCND1 polymorph-
ism at position A870G was significantly related to clini-
cal response (Figure 2, AA vs AG vs GG, p = 0.016).
Interestingly, an analysis restricted to patients with KRas
wt tumors confirms the predictive value of CCND1
A870G polymorphism on clinical response (AA vs AG
vs GG, p = 0.027), with the presence of the G allele
being associated with a lack of response (AA vs AG
+GG, p = 0.007, OR relative to GG+AG patients was
39.0, 95% CI 2.67-569.7). No relevant relationship was
observed for the other analyzed polymorphisms.
Impact of gene polymorphisms on TTP and specific
survival
Median TTP was 2.8 months. TTP was not influenced
by demographic or tumor characteristics, including
K-Ras mutation status, with the exception of a slight
influence of primary tumor localization (shorter TTP in
patients with right colon primary cancer, p = 0.027).
Univariate analyses showed that only -191C > A EGFR
Table 3 Distribution of gene polymorphisms
Gene Genotype N
EGFR CA-repeats (intron 1) Sum of CA ≤ 35 33
Sum of CA > 35 23
-216G>T GG 16
GT 29
TT 11
-191C>A CC 45
CA 11
AA 1
R497K RR 29
RK 18
KK 8
EGF 61A>G AA 25
AG 21
GG 9
CCND1 A870G AA 9
AG 35
GG 12
FCGR2A R131H RR 20
RH 29
HH 7
FCGR3A F158V FF 30
FV 20
VV 6
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Page 4 of 11and A870G CCND1 genotypes were related to TTP. Fig-
ure 3 shows a trend for a longer TTP in homozygous
EGFR -191CC patients relative to other patients (p =
0.050). CCND1 genotype had a significant impact on
TTP, with a longer TTP in AA patients relative to GG
patients and an intermediary TTP in heterozygous
patients (p = 0.037, Figure 4). Kaplan-Meier analyses
conducted in the sub-group of patients with KRas wt
tumors reinforced the influence of both EGFR -191C >
A (median 3.0 months in CC patients vs 2.6 months in
CA+AA patients p = 0.030) and CCND1 A870G (med-
ians 7.9, 3.0 and 2.6 months in AA, AG and GG
patients, respectively, p = 0.024) genotypes on TTP. A
multivariate stepwise Cox analysis including both gene
polymorphisms (considered as previously), on the whole
population, only retained CCND1 polymorphism (p =
0.057). This latter statistic became significant (CCND1 p
= 0.035, EGFR not retained in the analysis) in a multi-
variate stepwise analysis conducted on patients with
KRas wt tumors (relative risk of progression in GG
patients relative to AA patients was 5.59, 95% CI 1.36-
22.95; relative risk of progression in AG patients relative
to AA patients was 2.32, 95% CI 0.66-8.17).
Median specific survival was 8.4 months. Specific sur-
vival was influenced by neither demographic nor tumor
characteristics, including K-Ras mutation status. How-
ever, patients previously treated by bevacizumab had a
significantly shorter survival (median 4.9 months, 13
patients, 11 cancer-related deaths) than those who did
not receive bevacizumab (median 9.8 months, 44
patients, 33 cancer-related deaths, p = 0.018). Univariate
analyses revealed a significant influence of FCGR3A
F158V polymorphism on survival (FF vs FV vs VV, p <
0.001), with the 6 VV patients having a markedly shorter
survival (Figure 5). The influence of CCDN1 A870G
polymorphism was at the limit of significance (AA vs
AG vs GG, p = 0.050, Figure 6), with GG patients exhi-
biting the poorest survival. Other gene polymorphisms
had no influence on specific survival. Univariate analyses
conducted in the sub-group of patients with KRas wt
tumors confirmed the impact of FCGR3A F158V poly-
morphism on survival (median 9.9, 9.0 and 2.9 months
in FF, FV and VV patients, respectively, p = 0.003) and
reinforced the significance of CCND1 A870G poly-
morphism (medians 9.9, 9.9 and 2.9 months in AA, AG
and GG patients, respectively, p = 0.024). A multivariate
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Figure 1 Relationship between cetuximab-related acneiform rash (maximum observed grade) and CA-repeats polymorphism in intron
1o fEGFR gene (CA sum ≤ 35 vs CA sum > 35). Chi-square test: p = 0.058. OR relative to patients with CA sum > 35 was 2.91 (95% CI 0.95-
8.92).
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Figure 2 Relationship between best clinical response and CCND1 A870G gene polymorphism on the whole population. P value of chi-
square test was 0.016 for AA vs AG vs GG, 0.004 for AA vs AG+GG and 0.73 for AA+AG vs GG. Response rate was 6.4% in AG+GG patients and
11.9% in AA+AG patients.
y
*Included are samples recived for the study from BH Gampola, BH Nawalapitiya, GH Kandy and TH Peradeniya
Figure 3 TTP probability according to EGFR -191C > A gene polymorphism on the whole population. Median TTP was 2.9 months in CC
patients (43 patients, 38 events) vs 2.6 months in CA+AA patients (12 patients, 12 events); Log Rank test: p = 0.050.
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Page 6 of 11stepwise analysis conducted on the entire population,
including both gene polymorphisms considered as tern-
ary variables along with bevacizumab pre-treatment
(yes/no), revealed that CCND1 A870G (p = 0.044) and
FCGR3A F158V (p = 0.006) polymorphisms were signifi-
cant independent survival predictors (p = 0.014 for bev-
acizumab pre-treatment). Finally, this latter result was
confirmed in a multivariate stepwise analysis conducted
in the sub-group of patients with wt KRas tumors (p
values were 0.021, 0.036 and 0.058 for CCND1, FCGR3A
and bevacizumab pre-treatment, respectively).
Discussion
Cetuximab has shown efficacy in patients with metastatic
colorectal cancer in several phase II trials leading, in
2004, to FDA approval for the treatment of irinotecan-
refractory metastatic colorectal cancer. Several retrospec-
tive and prospective studies have clearly demonstrated
that KRAS mutation confers resistance to these patients
[6-10,23,24] but the complete mechanism of cetuximab
sensitivity remains only partially understood. The present
study was conducted in patients receiving cetuximab
before KRas-mutation testing was introduced as a
requirement. As expected, no response rate was observed
in mutated KRAS patients vs 15.2% in wt tumors, even
though the difference did not reach significance. We pre-
sently analyzed 8 gene polymorphisms involving 5 rele-
vant candidate genes potentially related to the
pharmacodynamics of cetuximab, namely EGFR, EGF,
CCND1, FCGR2A and FCGR3A, on 58 CRC patients
receiving cetuximab-based therapy. Statistical analyses
were conducted in the whole set of patients, as well as in
the sub-group of 34 patients with wt KRas tumors, so as
to reflect the current cetuximab-treated population.
Numerous studies have reported a relationship
between favorable outcome of cetuximab-treated patients
and related skin toxicity [2,3, 2 5 ] .A c c o r d i n g l y ,p r e s e n t
data show a higher response rate in patients developing
grade 2-3 cutaneous toxicity as compared to patients
with grade 0-1 (14% vs 5%, respectively), even though not
significant. Present results also show a tendency for an
association between intron 1 EGFR polymorphism and
cetuximab-related skin toxicity: the incidence of grade 2-
3 toxicity was 1.5-fold greater in patients bearing short
CA-repeats in intron 1 of EGFR gene (CA sum ≤ 35) as
compared to others (p = 0.058, Figure 1). This observa-
tion concords well with previous studies by Amador et al.
[26] and Graziani et al. [27] reporting that patients devel-
oping cutaneous rash after anti-EGFR therapies pre-
sented shorter CA-repeats in intron 1 of EGFR gene as
compared to patients who did not develop rash. Experi-
mental studies have reported an inverse correlation
between the number of CA-repeats in the intron 1 of the
EGFR gene and EGFR gene transcription [28-30]. It can
thus be hypothesized that elevated ubiquitous EGFR
expression (including skin and tumor) renders the cells
more susceptible to anti-EGFR effects.
In addition to the influence of intron 1 polymorphism
on EGFR gene transcription, EGFR gene presents two
functional polymorphisms in the promoter region: the
pg
Includes samples received from BH Kuliyapitiya and GH Kurunegala, excludes samples received from BH Dambadeniya as data
on DOA was not available.  
Figure 4 TTP probability according to CCND1 A870G gene polymorphism on the whole population. Median TTP was 6.3 months in AA
patients (7 patients, 6 events) vs 2.9 months in AG patients (35 patients, 31 events) vs 2.6 months in GG patients (12 patients, 12 events); Log
Rank test: p = 0.037. Comparison of AA+AG patients (median TTP 2.9 months) vs GG patients gave a p value at 0.016.
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[31,32], and the -191C/A polymorphism located 4 bp
upstream of a transcription initiation site [31]. These
two SNPs may thus have an impact on EGFR gene regu-
lation. Present data obtained on patients with wt KRas
tumors show a significantly longer TTP in homozygous
EGFR -191CC patients relative to other patients (p =
0.030, univariate analysis). However, this genotype was
not retained in a multivariate analysis.
Cyclin D1 is a downstream effector of EGFR signaling
that regulates cell cycle. The CCND1 A870G gene poly-
morphism affects the splice donor site at the exon 4/
intron 4 boundary, resulting in two different mRNA
transcripts (a and b) [33]. Both the A allele and the G
allele can encode these two transcripts. However, the A
allele preferentially encodes transcript b, which results
in a longer half-life cyclin D1 protein [33]. The impact
of CCND1 A870G polymorphism on cancer progression
has been studied in head and neck cancer patients, with
conflicting results [34,35]. In our study, patients homo-
zygous for the CCDN1 870AA genotype had a signifi-
cantly greater response rate than AG or GG patients,
both in the whole population and in patients with a wt
KRas tumor (75.0% vs 7.1%, respectively in wt KRas
patients). In addition, patients with the CCND1 870AA
genotype had a significantly longer median TTP than
GG patients, with AG patients having an intermediary
TTP, both in the whole population and in patients with
a wt KRas tumor (median TTP were 7.9, 3.0 and 2.6
months, in AA, AG and GG wt KRas patients, respec-
tively). Of note, in patients with wt KRas tumors,
CCND1 polymorphism also influenced specific survival,
with a significantly shorter survival in GG patients. The
positive influences of CCND1 870A allele are thus con-
sistent with one another, even though they do not con-
c o r dw i t ht h es o l ep u b l i s h e ds t u d yh a v i n ga n a l y z e dt h e
impact of CCND1 A870G polymorphism on the out-
come of advanced colorectal cancer patients receiving
cetuximab therapy [36]. In this latter study, conducted
on a limited sample of 39 patients, the 870 G allele had
a favorable impact on survival [36].
In addition to direct anti-EGFR effect, IgG1 mAbs
such as cetuximab mediate anti-tumor effects by the
ADCC mechanism. Fragment C of the mAb binds to
the Fc receptors (FcR) carried by immune cells, thus
triggering tumor cell lysis. Functional polymorphisms on
P
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1.0
0.8
0.6
0.4
0.2
0.0
Specific survival (months)
42 36 30 24 18 12 6 0
FF (N=29)
FV (N=20)
VV (N=6)
Figure 5 Specific survival (cancer-related death) probability according to FCGR3A F158V gene polymorphism on the whole
population. Median survival was 9.8 months in FF patients (29 patients, 21 events) vs 9.0 months in FV patients (20 patients, 15 events) vs 2.6
months in VV patients (6 patients, 6 events); Log Rank test: p < 0.001. Comparison of FF patients vs others was not significant (p = 0.31) whereas
comparison of VV patients vs others gave a p value < 0.001.
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Page 8 of 11two FcR genes (FCGR2A, FCGR3A) affecting the affinity
of FcR for fragment C have been identified [37,38].
These polymorphisms may thus influence ADCC effi-
ciency [39,40]. Even though some studies have reported
significant associations between these polymorphisms
and clinical efficacy of rituximab [41], trastuzumab [42]
or cetuximab [43,44], data conflict regarding which
alleles are linked to favorable patient outcome. In the
present study, we report a significant influence of
FCGR3A F158V polymorphism on survival both in the
whole population and in patients with a wt KRas tumor,
with VV patients presenting a dramatically shorter sur-
vival. The favorable influence of the FCGR3A 158F allele
was also reported in a study by Zhang et al. [43] and a
study by Pander et al. [45], but not in the study from
Bibeau et al. [44]. These discrepancies related to the
impact of FCGR3A 158F/V polymorphism on cetuximab
efficacy are difficult to account for but could be due to
the relatively limited sample size of these studies.
We observed that none of the 13 patients pre-treated
with bevacizumab had a response to cetuximab and that
this subgroup had a significantly decreased specific
survival as compared with non-pretreated patients (9.8
months vs 4.9 months, p = 0.018). This difference
remains statistically significant in a multivariate analysis
adjusted for age, sex, PS status and KRas status (data
not shown). This negative influence of bevacizumab pre-
treatment cannot be imputed to patient characteristics
which were not significantly different between bevacizu-
mab pretreated patients and non-pretreated patients,
although it must be noted that 42% of bevacizumab pre-
treated patients carried KRAS mutated tumors vs 29% in
non-pretreated patients (p = 0.48). Importantly, a multi-
variate analysis including bevacizumab pretreatment
revealed that CCND1 A870G and FCGR3A F158V poly-
morphisms both remained significant independent pre-
dictors of patient survival (whole population and KRas
wt tumors).
The retrospective design of this study, conducted on a
relatively small number of patients, may place intrinsic
limitations on the present original data. However, results
obtained in the sub-group of wt KRas patients, corre-
sponding to the current cetuximab-treated population,
clearly suggest that CCND1 A870G polymorphism may
Specific survival (months)
42 36 30 24 18 12 6 0
P
r
o
b
a
b
i
l
i
t
y
1.0
0.8
0.6
0.4
0.2
0.0
AA (N=8)
AG (N=35)
GG (N=12)
Figure 6 Specific survival (cancer-related death) probability according to CCND1 A870G gene polymorphism in the whole population.
Median survival was 9.9 months in AA patients (8 patients, 6 events) vs 9.0 months in AG patients (35 patients, 25 events) vs 4.7 months in GG
patients (12 patients, 11 events); Log Rank test: p = 0.050. Comparison of AA+AG patients (median survival 9.0 months) vs GG patients gave a p
value at 0.015.
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Page 9 of 11be used as an additional marker for predicting cetuxi-
mab efficacy, TTP and overall survival. Of note,
FCGR3A F158V polymorphism and CCND1 A870G
polymorphism were significant independent predictors
of overall survival in patients with wt KRas tumors.
Such promising observations deserve further confirma-
tion in a prospective study conducted on a larger popu-
lation of CRC patients receiving cetuximab-based
therapy.
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